Taipei Times: What major product lines will Boots offer Taiwanese consumers?
Martin Waters: Our company already has 1,400 chain stores in the UK with 2,500 products in three different categories that nobody else has, which is the first thing that we can offer to our customers.
We will import five exclusive brands of cosmetics under the Boots brandname, including No. 7 -- the number one brand of cosmetics in the UK, No. 17 which targets younger consumers, Natural Collection brand and the Kyusu label.
PHOTO: CHEN CHENG-CHANG, TAIPEI TIMES
In addition to that, we will compete with Boots products in the other core categories of skincare, hair care, body care, foot care and dental care -- anything to do with looking after your body is our business.
The other product line is health care, which includes 150 product supplements, from vitamins to a whole range of food supplements.
These products will take time to get in as they must be registered with and and approved by the Department of Health (
To begin with, we will probably only bring in about 100 to 150 products in the health care area. But we take a very long-term view of this market and plan to register far more products than that. We spent about a year to understand the health food and drug classifications in Taiwan.
TT: How will Boots present their products to customers?
Waters: First, we are experts in products, and second we are experts in people. We invest more money than any other retailer in the world on training. Our staff undergo intensive training programs before they meet customers. We do believe in having some staff who have more specialized knowledge than others -- specifically pharmacists.
We will have a pharmacist on duty in every shop, and I don't think anybody else does that. The second area of staff is the beauty section, where we will have specially trained make-up experts. The remaining staff will be for general assistance.
TT: Who are the competition in Taiwan?
Waters: Our business is split into three areas: beauty, personal care and health, so we compete with operators that dominate each of these specialized markets. In the health business we see ourselves competing with independent pharmacists. In the beauty market we recognize department stores as our competitors. In the personal care sector, grocers, hypermarts and convenience stores are the competition.
TT: Are there any unique marketing methods used by Boots?
Waters: Inside the shops our people will provide information customers can trust. We will explain ways to look after yourself, supplemented by a whole series of information leaflets on different subjects ranging from nail care to asthma.
TT: What products do you expect to be your strong suit in Taiwan?
Waters: We believe make-up will be especially popular here, due to the fact that Taiwan consumers are a bit more sophisticated when it comes to using the world's leading edge brands than other Asian markets.
We also expect some of our designer shampoos to be popular here as they bring a little more flair and expertise to the traditional shampoos customers have been using.
TT: When will the first store open and how many are planned?
Waters: The first Boots will be opening in September in Taipei, with another four to be set up by the end of this year. Meanwhile, the company plans to set up 100 outlets in five years.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Yageo Corp (國巨), the world’s third-largest supplier of multilayer ceramic capacitors, has formed a strategic alliance with Hon Hai Precision Industry Co (鴻海精密) to develop key electronic components for electric vehicles and digital healthcare, it said yesterday. The alliance is to help Yageo boost its revenue from high-end components for vehicles and industrial, medical and aerospace devices, as well as those used in 5G and Internet-of-Things devices, the company said. The companies signed the strategic alliance agreement at Yageo’s headquarters in New Taipei City’s Sindian District (新店). Their cooperation is to start this quarter, the companies said in a joint statement. “Through the cooperation
SUPPLY CONSTRAINTS: The transferred orders might not provide an immediate revenue boost given local chipmakers’ high utilization rates, a senior analyst said Shares of local contract chipmakers yesterday rose as much as the 10 percent daily limit, as investors bet on orders being transferred from Semiconductor Manufacturing International Corp (SMIC, 中芯國際) after the US imposed export restrictions on the Chinese chipmaker. United Microelectronics Corp (UMC, 聯電) shares soared 10 percent to close at NT$27.5 as 380 million shares changed hands on the Taiwan Stock Exchange. UMC is the world’s No. 3 foundry by revenue, followed by SMIC, according to data from market researcher TrendForce Corp (集邦科技). UMC has product and customer portfolios similar to those of SMIC, TrendForce said, adding that UMC offers 14-nanometer and
‘IMPORTANT MILESTONE’: The firm expects to launch the generic of Revlimid in the US after March 2022. It has already launched the product in some European countries Lotus Pharmaceutical Co Ltd (美時化學製藥) has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for lenalidomide, the company said in a statement on Friday. The ANDA approval is for 2.5mg, 5mg, 10mg, 20mg and 25mg capsules of lenalidomide, which is a generic version of blood cancer drug Revlimid developed by Celgene Corp. It is the first product fully developed and manufactured in Lotus’ facilities in Taiwan. Lotus expects to launch the product in the US — based on its patent litigation settlement with Celgene last year — some time after March